Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004459177 | SCV004950565 | uncertain significance | Inborn genetic diseases | 2024-01-23 | criteria provided, single submitter | clinical testing | The c.279G>C (p.K93N) alteration is located in exon 4 (coding exon 3) of the SLC34A1 gene. This alteration results from a G to C substitution at nucleotide position 279, causing the lysine (K) at amino acid position 93 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005038680 | SCV005671502 | uncertain significance | Hypophosphatemic nephrolithiasis/osteoporosis 1; Fanconi renotubular syndrome 2; Hypercalcemia, infantile, 2 | 2024-06-11 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004723590 | SCV005336763 | uncertain significance | SLC34A1-related disorder | 2024-08-29 | no assertion criteria provided | clinical testing | The SLC34A1 c.279G>C variant is predicted to result in the amino acid substitution p.Lys93Asn. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.028% of alleles in individuals of Latino descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |